Retrophin (NASDAQ: RTRX) and Regenxbio (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Insider & Institutional Ownership
68.7% of Regenxbio shares are held by institutional investors. 2.9% of Retrophin shares are held by company insiders. Comparatively, 17.0% of Regenxbio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of current ratings and price targets for Retrophin and Regenxbio, as reported by MarketBeat.
||Strong Buy Ratings
Retrophin currently has a consensus target price of $44.00, suggesting a potential upside of 89.82%. Regenxbio has a consensus target price of $43.17, suggesting a potential upside of 54.17%. Given Retrophin’s higher possible upside, equities analysts plainly believe Retrophin is more favorable than Regenxbio.
Valuation & Earnings
This table compares Retrophin and Regenxbio’s revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Retrophin has higher revenue and earnings than Regenxbio. Retrophin is trading at a lower price-to-earnings ratio than Regenxbio, indicating that it is currently the more affordable of the two stocks.
This table compares Retrophin and Regenxbio’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Retrophin beats Regenxbio on 7 of the 12 factors compared between the two stocks.
Retrophin Company Profile
Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
Regenxbio Company Profile
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.